ImaginAb
Inglewood
About ImaginAb
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $59.6M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2021)
- Website: imaginab.com
- Phone: 310-645-1211
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/imaginab-8457 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.